Jupiter Neurosciences, Inc.

Jupiter Neurosciences Doses First Parkinson’s Patient in JOTROL Phase 2a Trial
The Clinical Trial Vanguard · 08 Oct 2026
Jupiter Neurosciences Announces First Patient Dosed In Phase 2A Reset Trial In Parkinson’S Disease
TradingView · 06 Oct 2026
Jupiter Neurosciences Announces First Patient Dosed in
GlobeNewswire · 06 Oct 2026

Headlines from the last 30 days, linking to the original publishers. See all market news →

Disclaimer — PositoAI is a research and screening tool for educational and informational purposes. It is not investment advice or a recommendation to buy or sell any security or mutual fund. Scores and rankings are calculated by PositoAI's own method using publicly available data, which may be incomplete, delayed or inaccurate, and past performance does not indicate future results. AI summaries of company news may contain errors. PositoAI is not registered with the SEC, SEBI or any other regulatory authority. Please do your own research or consult a licensed financial advisor before investing.